Outset Medical (NASDAQ:OM) Shares Down 0.2% – Time to Sell?

Outset Medical, Inc. (NASDAQ:OM)’s stock price was down 0.2% on Wednesday . The company traded as low as $4.39 and last traded at $4.53. 93,061 shares were traded during mid-day trading, a decline of 70% from the average session volume of 310,987 shares. The stock had previously closed at $4.54.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of Outset Medical from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. TD Cowen reaffirmed a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Outset Medical in a report on Wednesday, June 24th. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $10.00.

Outset Medical Trading Down 3.7%

The company has a quick ratio of 4.97, a current ratio of 6.29 and a debt-to-equity ratio of 0.87. The business’s fifty day moving average is $4.45 and its two-hundred day moving average is $4.26. The firm has a market cap of $77.87 million, a price-to-earnings ratio of -1.01 and a beta of 1.95.

Outset Medical (NASDAQ:OM) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.04). The firm had revenue of $27.86 million for the quarter, compared to analyst estimates of $28.90 million. Outset Medical had a negative return on equity of 56.13% and a negative net margin of 63.65%. Equities analysts anticipate that Outset Medical, Inc. will post -3.82 earnings per share for the current fiscal year.

Insider Activity

In related news, CFO Renee Gaeta sold 17,672 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $4.94, for a total value of $87,299.68. Following the transaction, the chief financial officer owned 113,753 shares in the company, valued at $561,939.82. This trade represents a 13.45% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 25,337 shares of company stock worth $115,660 over the last quarter. Corporate insiders own 2.50% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in OM. BML Capital Management LLC boosted its stake in shares of Outset Medical by 250.2% in the 1st quarter. BML Capital Management LLC now owns 1,902,201 shares of the company’s stock valued at $7,304,000 after purchasing an additional 1,359,021 shares during the last quarter. Alyeska Investment Group L.P. lifted its holdings in Outset Medical by 10.2% in the third quarter. Alyeska Investment Group L.P. now owns 1,614,582 shares of the company’s stock valued at $22,798,000 after buying an additional 150,000 shares during the period. Ensign Peak Advisors Inc lifted its holdings in Outset Medical by 71.8% in the fourth quarter. Ensign Peak Advisors Inc now owns 560,169 shares of the company’s stock valued at $2,078,000 after buying an additional 234,082 shares during the period. Assenagon Asset Management S.A. boosted its stake in Outset Medical by 34.8% in the fourth quarter. Assenagon Asset Management S.A. now owns 508,414 shares of the company’s stock valued at $1,886,000 after acquiring an additional 131,381 shares during the last quarter. Finally, Millennium Management LLC boosted its stake in Outset Medical by 165.8% in the third quarter. Millennium Management LLC now owns 421,409 shares of the company’s stock valued at $5,950,000 after acquiring an additional 262,874 shares during the last quarter.

About Outset Medical

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.